Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (9675)	4/18/1999 12:02:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Opal April, it seems some, think you and I, would divert XOMA employees from there real task and have them spend an inordinate amount of time handholding and communicating with shareholders. Nothing could be farther from the truth. I understand, how much time and effort goes into or should go into the presentations at events or even the conference call. The point is that once that effort has been judged worthy of resource utilization, then there is only a marginal cost to sharing part of what was said with shareholders. I am quite forgiving,. I can imagine that on the hu1124 issue it had been decided to do a joint conference call with GNE, on the day of Castello's presentation at the Bio Century Conference. It takes time to set up such a call, promote it and prepare with the lawyers, GNE and roles of each speaker. Then, perhaps, GNE jumped the gun in mentioning P III in its' earnings report. My complaint is not that XOMA intended to hold up the announcement for a few days but rather that when GNE announced an agreement on P III, that XOMA insisted there were details yet to be resolved. I called GNE and I really doubt there was anything unresolved. XOMA IMO should have just said yes, GNE is right they announced earlier than expected as a joint conference call on the 15 th. had been planned. This would have ended the issue. Instead once again confidence in what XOMA says has been eroded.

To: opalapril who wrote (9675)	4/20/1999 10:05:00 AM
From: aknahow	Respond to of 17367

Some of us thought the trial could end early. We bought XOMA to some extent based on this. Only later did it become apparent that due to the existence of a pre established mandated mortality requirement the trial could not end early unless XOMA chose to give up or Neuprex was hurting the patients. There have been other incidents. I propose, voting all shares of record, even if one no longer holds all of them, against every management proposal. Remember, I urged everyone to support the move to Bermuda. I realize all this represents is symbolic effort. In addition there are no real crucial issues. The point is do posters and lurkers make any difference or not. Even with everyone of us voting all our shares against management I would expect all of management's proposals to pass by a wide margin. But if several hundreds of thousands, or even a million or so no votes are recorded management will get a message they understand better than angry post. VOTE NO! Don't forget to vote but, VOTE NO!